[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369178-105":59,"doc-detail-369178-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","monoclonal-antibodies-in-metastatic-gastro-esophageal-cancers-an-overview-of-the-latest-therapeutic-advances","Monoclonal Antibodies in Metastatic Gastro-Esophageal Cancers - An Overview of the Latest Therapeutic Advances","","Monoclonal antibodies (mAbs) have reshaped oncology by enabling major advances in cancer therapy over the past decades. Esophageal and gastric cancers, among the most commonly diagnosed worldwide, are increasingly managed with new therapeutic strategies, particularly mAbs. The review focuses on analysing current clinical trials of mAbs and immunotherapy in advanced gastroesophageal cancers, highlighting how combination treatments and emerging molecules are changing treatment outcomes and approvals.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/monoclonal-antibodies-in-metastatic-gastro-esophageal-cancers-an-overview-of-the-latest-therapeutic-advances/369178/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/monoclonal-antibodies-in-metastatic-gastro-esophageal-cancers-an-overview-of-the-latest-therapeutic-advances/369178.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this review?","Question",{"text":113,"@type":114},"To analyze major up-to-date clinical trials using monoclonal antibodies and immunotherapy for advanced gastroesophageal cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are monoclonal antibodies generated in the described field?",{"text":118,"@type":114},"They originate from a single B-lymphocyte clone and can be developed using hybridoma techniques, binding to a specific antigen epitope.",{"name":120,"@type":111,"acceptedAnswer":121},"Which molecular targets and therapies are discussed for gastric and esophageal cancers?",{"text":122,"@type":114},"The text highlights targets such as HER2 and VEGF-A, including therapies like trastuzumab and bevacizumab, alongside broader immunotherapy concepts.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369178,1790463108,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Review  \nMonoclonal Antibodies in Metastatic Gastro-Esophageal Cancers: An Overview of the Latest Therapeutic Advances  \nFoteini Kalofonou 1,*, Melpomeni Kalofonou 2, Foteinos-Ioannis Dimitrakopoulos 3 and Haralabos Kalofonos 3,4  \nAcademic Editor: Hidekazu Suzuki  \nReceived: 2 December 2024  \nRevised: 18 January 2025  \nAccepted: 22 January 2025  \nPublished: 27 January 2025  \nCitation: Kalofonou, F.; Kalofonou, M.; Dimitrakopoulos, F.-I.; Kalofonos, H. Monoclonal Antibodies in Metastatic Gastro-Esophageal Cancers:  \nAn Overview of the Latest Therapeutic Advances. Int. J. Mol. Sci. 2025, 26, 1090. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26031090  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Medical Oncology, The Royal Marsden NHS Trust, London SW3 6JJ, UK  \n2 Centre of Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London SW7 2AZ, UK  \n3 Division of Oncology, Department of Medicine, Medical School, University of Patras, 26504 Rion, Greece  \n4 Division of Oncology, Olympion General Clinic, 26443 Patras, Greece  \n* Correspondence: [foteini.kalofonou@rmh.nhs.uk](foteini.kalofonou@rmh.nhs.uk)  \nAbstract: Monoclonal antibodies (mAbs) have completely changed the face of oncology over the last 50 years, and they have contributed to a major breakthrough in terms of cancer therapy. Esophageal and gastric cancers, the eighth and fifth most commonly diagnosed types of cancer worldwide, respectively, have lately, been managed more effectively, with the introduction of new therapeutic treatment strategies, especially mAbs. Combination treatments and new molecules have changed the face of the disease, while more therapies are getting approved on a daily basis. This review aims to analyse the major up-to-date clinical trials using mAbs and immunotherapy for the treatment of advanced gastroesophageal cancers.  \nKeywords: monoclonal; antibodies; gastric; esophageal; cancer; hybridomas; immunoconjugates; biotechnology; progression free survival; overall survival; HER2; PDL-1; VEGF; trastuzumab; ipilimumab; nivolumab; zolbetuximab; margetuximab; pembrolizumab; tislelizumab; PD-1; CTLA4  \n1. Introduction  \nSince the initial introduction of the first mAb in 1975 and the first acquirement of its full license in 1986, the field of mAbs has exponentially developed and expanded. MAbs represent an innovative method of targeting specific mutations and protein structure malformations, in a wide range of diseases and conditions [1] . Due to the recent major advancements in molecular biology and especially in genetics, as well as in bio-technology, humanised mAbs are rapidly growing into pharmaceutical molecules with great clinical application and efficacy [2] .  \nMAbs derive from a single B-lymphocyte clone, binding to the same antigen, first generated in mice, using a hybridoma technique [3] . These mAbs bind to a specific epitope, which is the antigenic determinant of the antigen. MAbs generation using the hybridoma technology can be performed through in vitro or in vivo process, with these hybridomas containing initially a mixture of antibodies, which derive from many different primary B-lymphocyte clones [4] .  \nMAbs have evolved over the years, and the immunoconjugate technology used provides the attachement to a pharmaceutical component or drug, which can carry them around, via a chemical linker. These antibody–drug conjugates (ADCs) were designed to selectively deliver the cytotoxic chemical component of the drug directly to the target cells [5] . ADCs are often fragmented using separate analyses of individual analytes. As  \nsuch, it is difficul","cbCaiegU2CQt4gsZ","https://ap.wps.com/l/cbCaiegU2CQt4gsZ","pdf",694691,13,"English","# Introduction\n## Development and generation of mAbs\n## Antibody–drug conjugates (ADCs)\n## Epidemiology and unmet needs in metastatic disease\n## Molecular targets and rationale for mAb-based therapy","[{\"question\":\"What is the main purpose of this review?\",\"answer\":\"To analyze major up-to-date clinical trials using monoclonal antibodies and immunotherapy for advanced gastroesophageal cancers.\"},{\"question\":\"How are monoclonal antibodies generated in the described field?\",\"answer\":\"They originate from a single B-lymphocyte clone and can be developed using hybridoma techniques, binding to a specific antigen epitope.\"},{\"question\":\"Which molecular targets and therapies are discussed for gastric and esophageal cancers?\",\"answer\":\"The text highlights targets such as HER2 and VEGF-A, including therapies like trastuzumab and bevacizumab, alongside broader immunotherapy concepts.\"}]","Monoclonal Antibodies in Metastatic Gastro-Esophageal Cancers - An Overview of the Latest Therapeutic Advances | PDF",1790181210,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81a341d4fb84e08ebc8688dfff22444c.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4c890c4293f305254159a6b8a1ee581.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c991f4cff7a5337fe06e9d8f27a0ab2.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/404c199d1a26f499ed3b1db42cbf3053.webp",980,1385]